Many previous studies have shown that regular use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of developing colorectal cancer, but a new study is among the first to indicate that aspirin can also improve survival in patients who have already been diagnosed with colorectal cancers.
This news comes from Andrew Chan, MD, MPH, lead author of the study, which appeared in The Journal of the American Medical Association (2009;302: 649-658)…
However, other biomarkers—genetic biomarkers—are making targeted personalized treatments increasingly common among colorectal cancer patients. Mayo Clinic oncologist Axel Grothey, MD, discussed these developments in an article published in Therapeutic Advances in Medical Oncology (2009;1:55). “Biomarker-based treatment decisions are…now an integral part of clinical practice and trial design in colorectal cancer,” he wrote.
Oncology Nursing News, By Delicia Yard, 12/14/09